236 results match your criteria Biomarker research[Journal]


The emerging roles of N6-methyladenosine RNA methylation in human cancers.

Biomark Res 2020 29;8:24. Epub 2020 Jun 29.

Department of Hematology, the First Affiliated Hospital of Medical School of Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310003 Zhejiang China.

N6-methyladenosine (mA) is the most abundant form of mRNA modification in eukaryotes. It affects various aspects of RNA metabolism, including nuclear export, translation, decay and alternative splicing. In addition, mA also participates in a great number of human physiological processes, ranging from spermatogenesis modulation, response to heat shock, the control of T cell homeostasis to stem cell proliferation and differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00203-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325074PMC

Role of DNA repair defects in predicting immunotherapy response.

Biomark Res 2020 29;8:23. Epub 2020 Jun 29.

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.

Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defective mismatch repair has paved the way for investigating the role of other DDR defects in sensitizing cancer to ICB therapy. Despite great progress in understanding DDR pathways, the mechanisms that link DDR defects and ICB response remain incompletely understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00202-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325270PMC

Clinical characteristics and prognostic value of the mutation in Chinese non-small cell lung cancer patients.

Biomark Res 2020 25;8:22. Epub 2020 Jun 25.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, 106 Zhongshan Er Road, Guangzhou, 510080 China.

Background: The mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the -specific inhibitor AMG510 showed promising results in the phase I clinical trial. However, the frequency, clinical characteristics, and prognostic significance of the mutation in Chinese NSCLC patients are rarely reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00199-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318746PMC

Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment.

Biomark Res 2020 16;8:21. Epub 2020 Jun 16.

Department of Oncology, the First Affiliated Hospital of Zhengzhou University, NO.1 Eastern Jianshe Road, Zhengzhou, 450052 Henan China.

Myeloid-derived suppressor cells (MDSCs) are notable contributors to the immunosuppressive tumor microenvironment (TME) and are closely associated with tumor progression; in addition, MDSCs are present in most patients with cancer. However, the molecular mechanisms that regulate MDSCs in the etiopathogenesis of human tumor immunity remain unclear. The secreted alarmin high mobility group box 1 (HMGB1) is a proinflammatory factor and inducer of many inflammatory molecules during MDSC development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00201-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298841PMC

Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia.

Biomark Res 2020 12;8:20. Epub 2020 Jun 12.

Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.

Background: Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease and overall survival. However, its role in acute myeloid leukemia (AML) has not been sufficiently analyzed.

Methods: We investigated LOX plasma expression in 683 AML patients (age 17-60 years) treated within the prospective AML2003 trial (NCT00180102). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00200-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291659PMC

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.

Biomark Res 2020 3;8:19. Epub 2020 Jun 3.

State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

Background: Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T cells against solid tumors remains dissatisfactory, partially due to the heterogeneity of solid tumors and T cell exhaustion in tumor microenvironment. PD-L1 is up-regulated in multiple solid tumors, resulting in T cell exhaustion upon binding to its receptor PD-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00198-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268496PMC

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies.

Biomark Res 2020 27;8:18. Epub 2020 May 27.

Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253, Industrial Avenue, Guangzhou, Guangdong Province China.

Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. However, with extension of the follow-up period, the limitations of this therapy have gradually emerged. Patients are at a high risk of early relapse after achieving complete remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00197-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254656PMC

Advances in targeted therapy for acute myeloid leukemia.

Biomark Res 2020 20;8:17. Epub 2020 May 20.

4The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008 China.

Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment related mortality rate in the past few decades, long term overall survival has stagnated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00196-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238648PMC

Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study.

Biomark Res 2020 13;8:16. Epub 2020 May 13.

1Department of Urology, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200127 China.

Background: Identifying the temporal trends of kidney cancer (KC) incidence in both the past and the future at the global and national levels is critical for KC prevention.

Methods: We retrieved annual KC case data between 1990 and 2017 from the Global Burden of Disease (GBD) online database. The average annual percentage change (AAPC) was used to quantify the temporal trends of KC age-standardized incidence rates (ASRs) from 1990 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00195-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222434PMC

Circulating long non-coding RNA (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies.

Biomark Res 2020 13;8:15. Epub 2020 May 13.

1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance - Institute of the Ruhr University Bochum (IPA), Buerkle-de-la-Camp-Platz 1, 44789 Bochum, Germany.

Background: For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers.

Methods: Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00194-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222324PMC

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.

Biomark Res 2020 13;8:14. Epub 2020 May 13.

1Institute of Biomedical Engineering and Technology, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, NO, 3663 North Zhongshan Road, Shanghai, 200065 China.

Background: Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this antigen on immature plasma cells may limit the efficacy of this modality and facilitate relapse. The purpose of this study is to characterize a novel CAR that includes both a single-chain variable fragment (scFv)-BCMA and an scFv-CD19 in tandem orientation (tan-CAR) in an attempt to target both BCMA and CD19 expression on MM cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00192-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222432PMC

Biomarkers in individualized management of chimeric antigen receptor T cell therapy.

Biomark Res 2020 11;8:13. Epub 2020 May 11.

1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022 China.

The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission rates of CAR-T cell therapy in previously untreatable, refractory and/or relapsed patients, several challenges in CAR-T therapy remain to be overcome, especially in integrating such therapies into personalized disease management approaches. Given the unique characteristics of CAR-T therapy, it is particularly urgent to identify biomarkers to maximize their clinical benefits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00190-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216329PMC

Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report.

Biomark Res 2020 6;8:12. Epub 2020 May 6.

2Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Shizi street 188, Suzhou, 215006 China.

Background: Extramedullary relapse is an important cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). This type of relapse is commonly observed in the central nervous system, while it is rare in the testicles and skin. Chimeric antigen receptor-modified T cell (CAR-T) therapy targeting CD19 has shown to be a beneficial treatment approach for relapsed/refractory B cell acute lymphoblasticleukemia (r/r B-ALL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00193-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204010PMC

Overexpressed immunoglobulin-like transcript (ILT) 4 in lung adenocarcinoma is correlated with immunosuppressive T cell subset infiltration and poor patient outcomes.

Biomark Res 2020 29;8:11. Epub 2020 Apr 29.

1Department of Oncology, Jinan Central Hospital affiliated to Shandong University, Jinan, 250013 Shandong P. R. China.

Background: The poor response to current PD-1/PD-L1 inhibitors in lung cancer patients requires development of novel immunotargets. Immunoglobulin-like transcript (ILT)4 is an immunosuppressive molecule mainly expressed in myeloid innate cells. Recent studies showed that ILT4 was highly expressed in multiple malignant cells and regulated tumor biologies including proliferation, invasion and metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00191-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191800PMC

TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients.

Biomark Res 2020 17;8:10. Epub 2020 Apr 17.

1Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, National Center of Hematological Clinical Medicine Research, Shizi street 188, Suzhou, 215006 People's Republic of China.

Primary testicular lymphoma (PTL), often appearing as focal masses in the scrotum and epididymides, is the most frequent testicular tumor in aged men. Although MYD88 and CD79B mutations were the most common genetic alterations observed, the gene mutation landscape of PTL remains poorly defined. In this study, we identified 1326 mutations involving 311 genes or regions in 90 PTL patients through next-generation sequencing (NGS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00189-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164167PMC

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age.

Biomark Res 2020 9;8. Epub 2020 Apr 9.

1Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003 China.

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, its clinical impact on cancer immunotherapy is still largely unknown. Here we explored the influence of age, which is an important characteristic to evaluate immune response of patients, on TMB-based predictive system for ICIs therapy in NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00188-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146978PMC

LncRNA profile study reveals a seven-lncRNA signature predicts the prognosis of patients with colorectal cancer.

Biomark Res 2020 28;8. Epub 2020 Feb 28.

1School of Life Sciences, Chongqing University, Chongqing, 400044 People's Republic of China.

Background: The prognosis of colorectal cancer (CRC) is still challenging to evaluate or predict. Recently, long non-coding RNAs (lncRNAs) have been found to play an important role in tumorigenesis and prognosis, however, few lncRNAs have been identified in CRC progression. We aimed to establish a lncRNA signature to improve prognosis prediction of CRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-00187-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047379PMC
February 2020

The mir-767-105 cluster: a crucial factor related to the poor prognosis of hepatocellular carcinoma.

Biomark Res 2020 13;8. Epub 2020 Feb 13.

1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, 310003 China.

MiRNAs have been widely reported as the therapeutic target for hepatocellular carcinoma (HCC). However, mirna clusters, as the more impressive tumor regulatory factors, have received little attention. By deeply digging the Cancer Genome Atlas (TCGA) database, we aimed to explore the vital mirna cluster that regulated the poor prognosis of HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-0186-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020499PMC
February 2020

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.

Biomark Res 2020 13;8. Epub 2020 Feb 13.

2Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632 China.

Background: Altered expression of T cell immune inhibitory receptors may result in immunosuppression and associate with the poor prognosis of leukemia patients in which the leukemic bone marrow (BM) microenvironment may contribute to such immunosuppression. We found higher numbers of programmed death-1 (PD-1) + exhausted T cells in peripheral blood (PB) from acute myeloid leukemia (AML) patients. To investigate the leukemic BM influence on immunosuppression, we further compared the distributions of PD-1 and T cell immunoglobulin mucin-3 (Tim-3) and the exhausted T cell phenotype in PB and BM from AML patients and characterized their relationship with clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-0185-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020501PMC
February 2020

Using toponomics to characterize phenotypic diversity in alveolar macrophages from male mice treated with exogenous SP-A1.

Biomark Res 2020 13;8. Epub 2020 Feb 13.

1Penn State Center for Host defense, Inflammation, and Lung Disease (CHILD) Research and Departments of Pediatrics, The Pennsylvania State University College of Medicine, Hershey, PA 17033 USA.

Background: We used the Toponome Imaging System (TIS) to identify "patterns of marker expression", referred to here as combinatorial molecular phenotypes (CMPs) in alveolar macrophages (AM) in response to the innate immune molecule, SP-A1.

Methods: We compared 114 AM from male SP-A deficient mice. One group ( = 3) was treated with exogenous human surfactant protein A1 (hSP-A1) and the other with vehicle ( = 3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0181-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020580PMC
February 2020

Identification of pAKT as a pharmacodynamic marker for MER kinase in human melanoma G361 cells.

Biomark Res 2020 4;8. Epub 2020 Feb 4.

Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE 19803 USA.

Background: The MER signaling pathway represents an attractive therapeutic target for human cancers. Growth arrest-specific protein 6 (GAS6)-induced MER phosphorylation is often unstable and difficult to detect without pervanadate pretreatment in human cancer cells, posing a challenge for the development of selective MER kinase inhibitors. Here, we identified phosphorylated AKT (pAKT) as a specific pharmacodynamic marker for MER kinase inhibitors in human melanoma G361 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-0184-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001211PMC
February 2020

PSCA is a target of chimeric antigen receptor T cells in gastric cancer.

Biomark Res 2020 28;8. Epub 2020 Jan 28.

2Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530 China.

Background: Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-0183-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988264PMC
January 2020

Novel immunomodulatory drugs and neo-substrates.

Biomark Res 2020 9;8. Epub 2020 Jan 9.

1The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 127 Dongming Road, Zhengzhou, 450008 China.

Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematological malignancies. Recent studies showed that IMiDs bind to CRBN, a substrate receptor of CRL4 E3 ligase, to induce the ubiquitination and degradation of IKZF1 and IKZF3 in multiple myeloma cells, contributing to their anti-myeloma activity. Similarly, lenalidomide exerts therapeutic efficacy via inducing ubiquitination and degradation of CK1α in MDS with deletion of chromosome 5q. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-020-0182-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953231PMC
January 2020

LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.

Biomark Res 2020 8;8. Epub 2020 Jan 8.

1Departments of Biochemistry, Yonsei University Wonju College of Medicine, Wonju, Gangwon-do Republic of Korea.

Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to asbestos and results in a poor prognosis. Effective therapeutics as well as early diagnostics for the MPM are still lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0180-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950830PMC
January 2020

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer.

Biomark Res 2019 21;7:27. Epub 2019 Nov 21.

Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008 China.

EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have achieved remarkable outcomes in the treatment of patients with EGFR-mutant non-small-cell lung cancer, but acquired resistance is still the main factor restricting their long-term use. In addition to the T790 M mutation of EGFR, amplification of the MET (or c-MET) gene has long been recognized as an important resistance mechanism for first- or second-generation EGFR-TKIs. Recent studies suggest that a key mechanism of acquired resistance to third-generation EGFR-TKIs (such as osimertinib) may be MET amplification and/or protein overactivation, especially when they are used as a first-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0179-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873421PMC
November 2019

Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.

Biomark Res 2019 4;7:28. Epub 2019 Dec 4.

11Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse, 24 Chemin de Pouvourville, 31059 Toulouse, France.

Background: Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze cohort of TB3 and TC with a panel of antibodies to assess the prevalence of PD-L1 expression, its prognostic value and to set up a reproducible test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0177-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894111PMC
December 2019

Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma.

Biomark Res 2019 19;7:26. Epub 2019 Nov 19.

Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

Background: Tamoxifen treatment has previously been reported to confer life-prolonging effects in patients with advanced pancreatic cancer, and most evidently so in women. None of these trials did however include biomarkers, and the relevance of female hormone signaling in pancreatic or other periampullary adenocarcinoma remains largely unexplored. The aim of this study was to examine the extent and potential clinical significance of estrogen receptor-α (ER) and progesterone receptor (PR) expression in pancreatic and other periampullary cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0176-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862740PMC
November 2019

Cancer biomarkers for targeted therapy.

Authors:
Delong Liu

Biomark Res 2019 15;7:25. Epub 2019 Nov 15.

1New York Medical College, Valhalla, NY 10595 USA.

Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell engagers, and antibody-drug conjugates. Antibodies targeting CD19, CD20, CD22, CD30, CD33, CD38, CD79B and SLAMF7 are in clinical applications for hematological malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0178-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857213PMC
November 2019

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.

Authors:
Bo Yu Delong Liu

Biomark Res 2019 31;7:24. Epub 2019 Oct 31.

2Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY USA.

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for induction therapy of AML. When used in fractionated doses, GO combined with the conventional cytarabine/anthracycline-based induction chemotherapy significantly improves the outcome of previously untreated AML patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0175-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824118PMC
October 2019
1 Read

Epigenetic heterogeneity in cancer.

Biomark Res 2019 31;7:23. Epub 2019 Oct 31.

3The Hillman Cancer Center, University of Pittsburgh Cancer Institute, 5117 Centre Ave., Pittsburgh, PA 15213 USA.

Phenotypic and functional heterogeneity is one of the hallmarks of human cancers. Tumor genotype variations among tumors within different patients are known as interpatient heterogeneity, and variability among multiple tumors of the same type arising in the same patient is referred to as intra-patient heterogeneity. Subpopulations of cancer cells with distinct phenotypic and molecular features within a tumor are called intratumor heterogeneity (ITH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0174-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824025PMC
October 2019
1 Read

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia.

Biomark Res 2019 22;7:22. Epub 2019 Oct 22.

Department of Hematology, West China Hospital of Sichuan University, No.37 Guo Xue Xiang, Chengdu, 610041 Sichuan Province China.

Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and promotes leukemogenesis. IDH mutation occurs in 20% of acute myeloid leukemia (AML) patients, mainly including IDH1 R132, IDH2 R140, and IDH2 R172. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0173-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6806510PMC
October 2019

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

Biomark Res 2019;7:21. Epub 2019 Oct 17.

1Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

[This corrects the article DOI: 10.1186/s40364-019-0170-2.]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0172-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796449PMC
October 2019

Evaluation of breast stiffness measured by ultrasound and breast density measured by MRI using a prone-supine deformation model.

Biomark Res 2019 11;7:20. Epub 2019 Sep 11.

1John Tu and Thomas Yuen Center for Functional Onco-Imaging, University of California, 164 Irvine Hall, Irvine, CA 92697-5020 USA.

Background: This study evaluated breast tissue stiffness measured by ultrasound elastography and the percent breast density measured by magnetic resonance imaging to understand their relationship.

Methods: Magnetic resonance imaging and whole breast ultrasound were performed in 20 patients with suspicious lesions. Only the contralateral normal breasts were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0171-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737679PMC
September 2019
1 Read

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

Biomark Res 2019 11;7:19. Epub 2019 Sep 11.

1Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China.

FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-ITD and FLT3-TKD (tyrosine kinase domain) mutations are biomarkers for high risk AML and are associated with drug resistance and high risk of relapse. Multiple FLT3 inhibitors are in clinical development, including lestaurtinib, tandutinib, quizartinib, midostaurin, gilteritinib, and crenolanib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0170-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737601PMC
September 2019
1 Read

Mesothelin as a biomarker for targeted therapy.

Authors:
Jiang Lv Peng Li

Biomark Res 2019 23;7:18. Epub 2019 Aug 23.

1Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.

CAR-T cell therapy targeting CD19 has achieved remarkable success in the treatment of B cell malignancies, while various solid malignancies are still refractory for lack of suitable target. In recent years, a large number of studies have sought to find suitable targets with low "on target, off tumor" concern for the treatment of solid tumors. Mesothelin (MSLN), a tumor-associated antigen broadly overexpressed on various malignant tumor cells, while its expression is generally limited to normal mesothelial cells, is an attractive candidate for targeted therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0169-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708176PMC

Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?

Biomark Res 2019 7;7:17. Epub 2019 Aug 7.

1Peking University Peopl's Hospital, Peking University Institute of Hematology, No.11 Xizhimen South Street, Beijing, 100044 China.

Acute graft-versus-host disease (aGVHD) is one of the most important complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which would seriously affect the clinical outcomes of patients. Early diagnosis and early intervention are keys for improving its curative efficacy. Thus, seeking the biomarkers of aGVHD that can accurately identify and diagnose aGVHD is very important to guiding the intervention and treatment of aGVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0167-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685226PMC
August 2019
1 Read

Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer.

Biomark Res 2019 6;7:16. Epub 2019 Aug 6.

1Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023 China.

Background: The peroxiredoxins (PRDXs) gene family has been demonstrated to participate in carcinogenesis and development of numerous cancers and the prognostic values in several cancers have been evaluated already. Purpose of our research is to explore the expression profiles and prognostic values of PRDXs in breast cancer (BrCa).

Methods: The transcriptional levels of PDRX family members in primary BrCa tissues and their association with intrinsic subclasses were analyzed using UALCAN database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0168-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683561PMC

Targeted therapies for myeloproliferative neoplasms.

Biomark Res 2019 16;7:15. Epub 2019 Jul 16.

1MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020 China.

The discovery of V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment in the treatment of MPNs, representing the first targeted treatment in this field. Despite a weak effect on the cause of the disease itself in MPNs, ruxolitinib improves the clinical state of patients and increases survival in myelofibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0166-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636147PMC
July 2019
1 Read

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Biomark Res 2019 16;7:14. Epub 2019 Jul 16.

1Free Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA USA.

Background: The epidermal growth factor receptor (EGFR) monoclonal IgG antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high response and disease control rates but is generally not curative and many patients will experience recurrent disease and/or metastasis. Therefore, there is a great need to identify predictive biomarkers for recurrence and disease progression in cetuximab-treated HNSCC patients to facilitate patient management and allow for treatment modification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0164-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636109PMC
July 2019
2 Reads

DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells.

Biomark Res 2019 8;7:13. Epub 2019 Jul 8.

Seattle Institute for Biomedical and Clinical Research, VA Puget Sound Healthcare System, 1660 South Columbian Way, S-111-ONC, Seattle, WA 98108 USA.

Background: The MPL protein is a major regulator of megakaryopoiesis and platelet formation as well as stem cell regulation. Aberrant MPL and downstream Jak/STAT signaling results in the development of the Myeloproliferative Neoplasms (MPN). The pathogenetic and phenotypic features of the classical MPNs cannot be explained by the known mutations and genetic variants associated with the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0165-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615210PMC
July 2019
1 Read

Identification of 11-2-1-1-1 T cell clone specific for WT1 peptides using high-throughput gene sequencing.

Biomark Res 2019 14;7:12. Epub 2019 Jun 14.

1Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, 601 Huang Pu Da Dao Xi, 510632 Guangzhou, People's Republic of China.

We previously identified a 21 T cell clone which was specific to CML patients, and demonstrated that 13/21 gene-modified CD3 T cells had specific cytotoxicity for HLA-A11 K562 cells. However, it remains unclear which antigen is specifically recognized by the 21 T cell clone. In this study, CD3 T cells from healthy donor peripheral blood were stimulated with the WT1 peptide or mixed BCR-ABL peptides in the presence or absence of IL-2 and IL-7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0163-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570921PMC
June 2019
12 Reads

Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge.

Authors:
Da Gao Zach Liu

Biomark Res 2019 3;7:11. Epub 2019 Jun 3.

2Department of Pathology Rutgers University, New Brunswick, NJ USA.

Background: A subset of diffuse large B-cell lymphoma may show aberrant cyclin D1 expression, which may be confused with blastoid mantle cell lymphoma. These cases usually lack of CCND1 gene rearrangement. Duplication of CCND1 gene was attributed to some of the cases with cyclin D1 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0162-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547582PMC
June 2019
3 Reads

Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adults.

Biomark Res 2019 28;7:10. Epub 2019 May 28.

1Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN USA.

Background: Changes in DNA methylation over the course of life may provide an indicator of risk for cancer. We explored longitudinal changes in CpG methylation from blood leukocytes, and likelihood of future cancer diagnosis.

Methods: Peripheral blood samples were obtained at baseline and at follow-up visit from 20 participants in the Health, Aging and Body Composition prospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0161-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537435PMC
May 2019
13 Reads

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Biomark Res 2019 11;7. Epub 2019 Apr 11.

1Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.

B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0160-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458768PMC
April 2019
5 Reads

Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm.

Biomark Res 2019 4;7. Epub 2019 Apr 4.

1Center of Excellence in Tissue Engineering, Department of cell biology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.

Mesenchymal stem/stromal cells (MSCs) have been demonstrated to hold great potential for the treatment of several diseases. Their therapeutic effects are largely mediated by paracrine factors including exosomes, which are nanometer-sized membrane-bound vesicles with functions as mediators of cell-cell communication. MSC-derived exosomes contain cytokines and growth factors, signaling lipids, mRNAs, and regulatory miRNAs. Read More

View Article

Download full-text PDF

Source
https://biomarkerres.biomedcentral.com/articles/10.1186/s403
Publisher Site
http://dx.doi.org/10.1186/s40364-019-0159-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450000PMC
April 2019
14 Reads

The association between early neurological deterioration and whole blood purine concentration during acute stroke.

Biomark Res 2019 3;7. Epub 2019 Apr 3.

1NIHR Newcastle Biomedical Research Centre and Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.

Background: Early neurological deterioration (END) is common after stroke. Prediction could identify patients requiring additional monitoring and intervention. Purines, breakdown products of adenosine triphosphate which accumulate during acute hypoxia, may reflect the subclinical presence of vulnerable tissue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0158-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448300PMC
April 2019
7 Reads

Novel insights into MSC-EVs therapy for immune diseases.

Biomark Res 2019 18;7. Epub 2019 Mar 18.

1Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080 People's Republic of China.

Mesenchymal stromal cells (MSC) are a heterogeneous cell population with self-renewal and the ability to differentiate into different lineages. The novel regulatory role of MSC in both adaptive and innate immune responses got extensive investigation and MSC have been widely used in clinical trials as immunosuppressive agents for autoimmune and inflammatory diseases, including graft-versus-host disease (GVHD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), chronic kidney disease, etc. Recent studies have found that MSC exerted their immunomodulation function through secreting extracellular vesicles (EVs), which delivered parent cell cargo to recipient cells without oncogenicity or variability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0156-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423844PMC
March 2019
18 Reads

Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.

Biomark Res 2019 8;7. Epub 2019 Mar 8.

1Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK USA.

Background: Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) incidence has been increasing in the United States for greater than 30 years. For the majority of EAC patients, treatment is limited and prognosis poor. Doublecortin like kinase-1 (DCLK1) is a cancer stem cell marker with elevated expression in BE patients with high grade dysplasia and/or EAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0157-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408757PMC
March 2019
18 Reads

The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients.

Biomark Res 2019 22;7. Epub 2019 Feb 22.

1Department of Pathology& Laboratory Medicine, Aga Khan University Hospital (AKUH), Stadium Road, P.O. Box 3500, Karachi, 74800 Pakistan.

In current clinical practice, Serum Creatinine (SCr) is a commonly used marker for the diagnosis of acute kidney injury (AKI). Unfortunately, due to a delayed increase in SCr, it is unable to accurately estimate the timing of the injury. The purpose of this study was to assess the ability of plasma neutrophil gelatinase-associated lipocalin (pNGAL) to predict AKI in critically ill adult patients The study was conducted at the Section of Chemical Pathology, Department of Pathology& Laboratory Medicine in collaboration with Department of Anesthesiology, at Aga Khan University Hospital in Karachi, Pakistan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0155-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387517PMC
February 2019
5 Reads

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Biomark Res 2019 12;7. Epub 2019 Feb 12.

1Department of Neurology, Flinders Medical Centre, Bedford Park, South Australia 5042 Australia.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterised by significant clinical heterogeneity and as such reliable biomarkers are required to measure disease activity and assess treatment response. Recent advances in our understanding of disease pathogenesis and the discovery of novel serum-based, electrophysiologic and imaging biomarkers allow clinicians to make more informed decisions regarding individualised treatment regimes. As a chronic immune-mediated process typified by relapse following withdrawal of immunomodulatory therapy, a substantial proportion of patients with CIDP require long term treatment with intravenous immunoglobulin (IVIg), a scarce and expensive donor-derived resource. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40364-019-0154-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373155PMC
February 2019
5 Reads